Cargando…
Recent advances in understanding and managing hairy cell leukemia
Hairy cell leukemia is a rare B-cell malignancy that is characterized by an indolent course. It was initially described as a distinct entity in 1958. Before the establishment of modern treatment, median survival was only 4 years. Since then, major advances in the treatment and understanding of the b...
Autores principales: | Roider, Tobias, Falini, Brunangelo, Dietrich, Sascha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931274/ https://www.ncbi.nlm.nih.gov/pubmed/29770206 http://dx.doi.org/10.12688/f1000research.13265.1 |
Ejemplares similares
-
Genomics of Hairy Cell Leukemia
por: Tiacci, Enrico, et al.
Publicado: (2017) -
Treatment of Classic Hairy Cell Leukemia: Targeting Minimal Residual Disease beyond Cladribine
por: Bohn, Jan-Paul, et al.
Publicado: (2022) -
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
por: Grever, Michael, et al.
Publicado: (2021) -
Gene Expression Profiling of Hairy Cell Leukemia Reveals a Phenotype Related to Memory B Cells with Altered Expression of Chemokine and Adhesion Receptors
por: Basso, Katia, et al.
Publicado: (2004) -
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial
por: Tiacci, Enrico, et al.
Publicado: (2021)